Palvella Races Toward Key 2026 Readouts as Rare-Disease Pipeline Expands Rapidly
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) reported third-quarter results and detailed an intensifying slate of clinical milestones as its QTORIN platform advances across four rare dermatologic diseases — …
Palvella Races Toward Key 2026 Readouts as Rare-Disease Pipeline Expands Rapidly Read More